转移性激素无效前列腺癌：一种独特的生物学实体。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI:10.1016/j.trecan.2024.06.005

Jon Corres-Mendizabal, Francesca Zacchi, Natalia Martín-Martín, Joaquin Mateo, Arkaitz Carracedo

{"title":"转移性激素无效前列腺癌：一种独特的生物学实体。","authors":"Jon Corres-Mendizabal, Francesca Zacchi, Natalia Martín-Martín, Joaquin Mateo, Arkaitz Carracedo","doi":"10.1016/j.trecan.2024.06.005","DOIUrl":null,"url":null,"abstract":"Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":14.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11397905/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metastatic hormone-naïve prostate cancer: a distinct biological entity.\",\"authors\":\"Jon Corres-Mendizabal, Francesca Zacchi, Natalia Martín-Martín, Joaquin Mateo, Arkaitz Carracedo\",\"doi\":\"10.1016/j.trecan.2024.06.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11397905/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.06.005\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.06.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

转移性激素无效前列腺癌（mHNPC）通常是转移性前列腺癌的最初表现形式，它包括一个在预后和治疗反应方面具有高度异质性的异质性患者群体。以循证生物标志物为指导，对 mHNPC 进行更精确的治疗，仍是一项尚未满足的医疗需求。此外，具有代表性的 mHNPC 实验室模型数量有限，阻碍了基础研究向临床应用的转化。我们全面概述了 mHNPC 的临床和生物学特征，重点介绍了可以解释 mHNPC 独特预后特征的分子数据，并确定了关键的开放性问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metastatic hormone-naïve prostate cancer: a distinct biological entity.

Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.